Annual Anaqua Analysis of USPTO Data Finds Strong Increase in Patent Grant Activity 30-01-2025, 19:00

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia 21-09-2024, 15:15

Bitget KCGI 2025 Heats Up as Team Battle Kicks Off: Communities Unite, Rivalries Ignite 25-07-2025, 11:00